STTK Sep 2024 17.500 call
| Previous close | 1.3500 |
| Open | 1.3500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 17.50 |
| Expiry date | 2024-09-20 |
| Day's range | 1.3500 - 1.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Most Shareholders Will Probably Agree With Shattuck Labs, Inc.'s (NASDAQ:STTK) CEO Compensation
Key Insights Shattuck Labs' Annual General Meeting to take place on 7th of June Salary of US$525.0k is part of CEO...
ZacksAfter Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GlobeNewswireShattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL-172154 continued to demonstrate an acceptable safety profile in combination with AZA – – EHA poster presentation to include additional data from the next planned data cutoff in the second quarter of 2024 – AUSTIN, TX and DURHAM, NC, May 14, 2024 (GLOBE NEWS
